Abstract

Type 1 diabetes (T1D) in pediatric populations presented unique therapeutic challenges, with suboptimal glycemic 
control contributing to acute complications and long-term microvascular disease despite advances in insulin delivery 
technologies. Smart insulin patch systems represented an emerging paradigm combining glucose-responsive 
materials, microneedle technology, and biocompatible polymers to achieve autonomous insulin delivery mimicking 
physiological β-cell function without electronic components or continuous glucose monitoring integration. This 
narrative review critically evaluated the biochemical mechanisms, preclinical evidence, and translational potential of 
smart insulin patches specifically for pediatric T1D management. A comprehensive literature search of PubMed, 
Embase, and Web of Science databases (2015–2025) was conducted using terms including "smart insulin patch," 
"glucose-responsive," "microneedle," "pediatric diabetes," and "closed-loop delivery." Principal findings 
demonstrated that glucose-oxidase-based, phenylboronic acid-modified, and glucose-binding protein-incorporating 
patches achieve rapid insulin release in hyperglycemic conditions with substantially reduced hypoglycemia risk in 
preclinical models. Microneedle arrays enabled painless transdermal delivery with enhanced patient acceptability, 
particularly relevant for pediatric populations experiencing needle anxiety and compliance challenges. However, 
translation to clinical practice remained constrained by limited bioresponsiveness kinetics, inadequate release 
dynamics for postprandial glycemic excursions, biocompatibility concerns with repeated applications, and absence 
of pediatric-specific clinical trials. Smart insulin patches offered promising potential for revolutionizing pediatric 
T1D management contingent upon optimization of responsiveness, durability, and rigorous clinical validation in 
younger populations.